Leave R&D tax credits alone, warns Medicines Australia
This article was originally published in Scrip
Executive Summary
Winding back Australia's R&D tax credit system could cause some companies to stop bringing R&D investment dollars to Australia, warned Dr Brendan Shaw, chief executive of Medicines Australia, in a statement today. His comments come in response to Australian media reports that the government may change the tax credit system in the forthcoming federal budget.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.